IL2 and graft versus host disease: Exogenous IL-2 administration has been ascribed to be deleterious in GVHD owing to its ability to promote effector T cell function, although when given in high doses for several days beginning on transplant day 0, allo-HSCT recipient mice had markedly diminished GVHD [155,156].